Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Intravenous propranolol in patients with inflammation.

Literature DB >> 7066175

Intravenous propranolol in patients with inflammation.

D G Waller, C L Smith, A G Renwick, C F George.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：
Propranolol

Year: 1982 PMID： 7066175 PMCID： PMC1402065 DOI： 10.1111/j.1365-2125.1982.tb01426.x

Source DB: PubMed Journal: Br J Clin Pharmacol ISSN： 0306-5251 Impact factor: 4.335

× No keyword cloud information.

6 in total

1. Plasma levels of propranolol in treated patients with coeliac disease and patients with Crohn's disease.

Authors: R E Schneider; J Babb; H Bishop; M Mitchard; A M Hoare
Journal: Br Med J Date: 1976-10-02

2. Plasma binding and the affinity of propranolol for a beta receptor in man.

Authors: D G McDevitt; M Frisk-Holmberg; J W Hollifield; D G Shand
Journal: Clin Pharmacol Ther Date: 1976-08 Impact factor: 6.875

3. High-pressure liquid chromatographic method for the simultaneous quantitative analysis of propranolol and 4-hydroxypropranolol in plasma.

Authors: R L Nation; G W Peng; W L Chiou
Journal: J Chromatogr Date: 1978-05-01

4. Absorption of propranolol and practolol in Coeliac disease.

Authors: R L Parsons; C M Kaye; K Raymond; J R Trounce; P Turner
Journal: Gut Date: 1976-02 Impact factor: 23.059

5. Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein.

Authors: K M Piafsky; O Borgá; I Odar-Cederlöf; C Johansson; F Sjöqvist
Journal: N Engl J Med Date: 1978-12-28 Impact factor: 91.245

6. Plasma propranolol concentrations and the erythrocyte sedimentation rate.

Authors: R E Schneider; H Bishop; C F Hawkins
Journal: Br J Clin Pharmacol Date: 1979-07 Impact factor: 4.335

6 in total

1. Drug-disease interaction: Crohn's disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activity.

Authors: Forough Sanaee; John D Clements; Alistair W G Waugh; Richard N Fedorak; Richard Lewanczuk; Fakhreddin Jamali
Journal: Br J Clin Pharmacol Date: 2011-11 Impact factor: 4.335

Intravenous propranolol in patients with inflammation.

1. Plasma levels of propranolol in treated patients with coeliac disease and patients with Crohn's disease.

2. Plasma binding and the affinity of propranolol for a beta receptor in man.

3. High-pressure liquid chromatographic method for the simultaneous quantitative analysis of propranolol and 4-hydroxypropranolol in plasma.

4. Absorption of propranolol and practolol in Coeliac disease.

5. Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein.

6. Plasma propranolol concentrations and the erythrocyte sedimentation rate.

1. Drug-disease interaction: Crohn's disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activity.

2. Pharmacology of propranolol in patients with cirrhosis and portal hypertension.

3. Food, drugs, and bioavailability.

4. The absorption and conjugation of methyldopa in patients with coeliac and Crohn's diseases during treatment.

5. The protein binding of timegadine determined by equilibrium dialysis.

6. Binding to serum alpha 1-acid glycoprotein and effect of beta-adrenoceptor antagonists in rats with inflammation.